About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients

NCT03011749·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Rigshospitalet, Denmark

Age

Any age

Sex

MALE

Healthy volunteers

Not accepted

You may be eligible if

Metastatic castration resistant prostate cancer
Eligible for Radium-223 therapy
Informed consent

You may not be if

Inability to understand study protocol
Extensive metastatic involvement of the axial skeleton ("superscan" on bone scintigraphy)

The record

StatusTerminated

PhaseNo phase

Taking part6

StartedJan 2017

UpdatedSep 12, 2019

Conditions

Metastatic Prostate Carcinoma

Where1

Rigshospitalet
Copenhagen, Denmark

Clareo Health | Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients